Page 64 - e-CPG-SLE-8_5_24

Management of Systemic Lupus Erythematosus

18. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology
guidelines for screening, treatment, and management of lupus nephritis. Arthritis
Care Res (Hoboken). 2012;64(6):797-808.
19. Huang D, Aghdassi E, Su J, et al. Prevalence and risk factors for liver biochemical
abnormalities in Canadian patients with systemic lupus erythematosus. J
Rheumatol. 2012;39(2):254-261.
20. Yip J, Aghdassi E, Su J, et al. Serum albumin as a marker for disease activity
in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(8):1667-
1672.
21. Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for
Rheumatology guideline for the management of systemic lupus erythematosus
in adults. Rheumatology (Oxford). 2018;57(1):e1-e45.
22. American College of Rheumatology Ad Hoc Committee on Immunologic Testing
Guidelines. Guidelines for Immunologic Laboratory Testing in the Rheumatic
Diseases: An Introduction. Arthritis Rheum. 2002;47(4):429-433.
23. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against
Rheumatism/American College of Rheumatology Classification Criteria for
Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412.
24. Pisetsky DS. Anti-DNA antibodies--quintessential biomarkers of SLE. Nat Rev
Rheumatol. 2016;12(2):102-110.
25. Irure-Ventura J, Lopez-Hoyos M. Disease criteria of systemic lupus
erythematosus (SLE); the potential role of non-criteria autoantibodies. J Transl
Autoimmun. 2022;5:100143.
26. Huang C, Li M, Liu Y, et al. Baseline Characteristics and Risk Factors of
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients.
Medicine (Baltimore). 2016;95(10):e2761.
27. Tarr T, Lakos G, Bhattoa HP, et al. Analysis of risk factors for the development
of thrombotic complications in antiphospholipid antibody positive lupus patients.
Lupus. 2007;16(1):39-45.
28. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun.
2000;15(2):145-151.
29. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic
Lupus International Collaborating Clinics classification criteria for systemic lupus
erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.
30. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on
an update of the classification criteria for definite antiphospholipid syndrome
(APS). J Thromb Haemost. 2006;4(2):295-306.
31. Mannes M, Schmidt CQ, Nilsson B, et al. Complement as driver of systemic
inflammation and organ failure in trauma, burn, and sepsis. Semin Immunopathol.
2021;43(6):773-788.
32. Lintner KE, Wu YL, Yang Y, et al. Early Components of the Complement
Classical Activation Pathway in Human Systemic Autoimmune Diseases. Front
Immunol. 2016;7:36.
33. Kuhn A, Bonsmann G, Anders HJ, et al. The Diagnosis and Treatment of
Systemic Lupus Erythematosus. Dtsch Arztebl Int. 2015;112(25):423-432.
34. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification
of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-1277.
35. Hochberg MC. Updating the American College of Rheumatology revised
criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.
1997;40(9):1725.
36. Inês L, Silva C, Galindo M, et al. Classification of Systemic Lupus Erythematosus:
Systemic Lupus International Collaborating Clinics Versus American College of
Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-

47